Skip to main contentSkip to navigationSkip to search

Press release

New date for publication of Camurus’ Annual Report 2018

26 March 2019

Lund, Sweden — 26 March 2019 — Camurus (NASDAQ STO: CAMX) has updated its financial calendar. New date for publication of the Annual Report for 2018 is 15 April 2019. As previously communicated the Annual General Meeting will be held on 9 May 2019.

About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92

Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37

This information was submitted for publication at 8:00 am CET on 26 March 2019.

TypeError: Cannot read properties of undefined (reading 'url')